Rejected from Biotechnology Advances? The 6 Best Journals to Submit Next

Match the next venue to what the editor actually flagged. If the problem was scope or synthesis depth, stay in the review-journal lane. If the manuscript is really primary data, move to a research journal that wants it.

Source: Clarivate JCR 2024, SCImago (SJR), and each journal's Elsevier, Cell Press, Taylor & Francis, or Wiley guide for authors (accessed June 2026).

A few words on each, because the table alone hides the editorial logic.

Trends in Biotechnology (Cell Press) is the reach. Reviews and opinions are generally commissioned by the editor, then put through stringent peer review. If your Biotechnology Advances reject was on synthesis depth rather than scope, this is a harder, not easier, target. Use the presubmission inquiry path before you assume you can submit unsolicited.

Critical Reviews in Biotechnology (Taylor & Francis) is the closest direct analogue. It exists for critical evaluation of recent work across food, fuel, chemical, pharmaceutical, and waste-management biotechnology. If your manuscript was a genuine critical review that Biotechnology Advances found too narrow, this is the natural next stop.

Current Opinion in Biotechnology (Elsevier) wants short, topical, themed reviews. If Biotechnology Advances said your review tried to cover too much, a tighter Current Opinion piece on one theme can land where a sprawling synthesis would not. As an Elsevier title, it is a common Article Transfer Service destination.

Metabolic Engineering (Elsevier) is the honest home if your "review" is really primary engineering data. It publishes original research on metabolic, cellular, and pathway engineering and moves quickly. Another in-house transfer candidate.

Bioresource Technology (Elsevier) takes high-volume primary research in bioprocess, bioenergy, and environmental biotechnology. If your work is experimental rather than a synthesis, this is a faster, more accepting route. See the Bioresource Technology submission guide for its scope boundaries.

Biotechnology Journal (Wiley) is the step down in selectivity for applied research and shorter reviews that need a credible, indexed home without the top-tier review bar.

Run a Biotechnology Advances manuscript fit check to see whether your synthesis is review-journal shaped or research-journal shaped before you pick the next venue.

Biotechnology Advances submits through the Elsevier system and participates in the Elsevier Article Transfer Service. That changes your cascade in one concrete way: if the editor judges the manuscript a better fit for a sibling title, you may receive a transfer offer by email rather than a flat reject. The offer expires after about 130 days, and a declined or ignored offer is treated as a decline.

If you got a transfer offer, take it seriously. Transferred articles carry your files and reviewer reports forward and reach acceptance roughly 10 days faster than fresh submissions. The likely in-house destinations are Current Opinion in Biotechnology (if the review is too broad and needs a themed cut), Metabolic Engineering (if it is primary engineering data), or Bioresource Technology (if it is experimental bioprocess work).

If you got a flat reject with no transfer, build the ladder by manuscript type, not by impact factor. Match what the editor flagged to the right next venue:

Source: editorial scope statements from each journal's Elsevier, Cell Press, Taylor & Francis, or Wiley guide for authors (accessed June 2026).

In our pre-submission review work with Biotechnology Advances submissions, the rejections we see most are not about wrong science. They are about the gap between a literature summary and a load-bearing critical synthesis, and they are testable before you resubmit anywhere.

The review describes the field but never takes a position. This is the single most common pattern we see in Biotechnology Advances manuscripts. The review walks through recent advances in chronological or thematic order, but it never argues which approach is industrially, environmentally, or therapeutically viable and which is a dead end.

Biotechnology Advances editors reject these before external review because the journal exists to publish reviews that change a practitioner's next decision, not reviews that restate the literature. Test your manuscript: can a reader name the single defensible claim the review is making, in one sentence, from the abstract alone? If not, the critical synthesis is missing.

The application pathway is named in the title but not argued in the body. Across our pre-submission reviews of Biotechnology Advances manuscripts, we repeatedly see reviews that promise industrial bioprocessing, environmental remediation, or therapeutic translation in the title and abstract, then spend the body on basic mechanism with the application appearing only as a closing paragraph.

Biotechnology Advances is an applied review journal; the application has to be the spine of the synthesis, not a coda. Check whether every major section ties back to a deployment bottleneck. If the application logic only lives in the introduction and conclusion, the review reads as basic biology to the editor.

The figures are reused conceptual schematics rather than original synthesis. A review at this tier is judged partly on whether its figures do analytical work. We frequently flag manuscripts whose schematics are recognizable from prior reviews by the same group or from textbooks, contributing nothing new to the argument.

Biotechnology Advances reviewers expect at least one figure that organizes the field in a way no existing review has, for example a decision tree across competing platforms or a quantitative comparison table of approaches. If your figures could be lifted into any review on the topic without changing the meaning, they will not carry the synthesis.

Redundancy with an existing review the editor already knows. Because Biotechnology Advances publishes few items per year, editors track what the field already has. We see desk rejects where a recent Critical Reviews in Biotechnology or Current Opinion in Biotechnology piece already covered the same ground, and the new manuscript does not establish what it adds. Before resubmitting, search the last three years of competing review journals for your exact topic and state, in the cover letter, the specific gap your review fills that the existing ones do not.

Reference comprehensiveness is broad but shallow. Reviews here are expected to be comprehensive, with up to roughly 200 references, but breadth without curation is a tell. We see reference lists that pad with tangential citations while missing the two or three foundational engineering papers a specialist editor expects. A reviewer who knows the subfield notices an absent landmark immediately. Audit the reference list against the most-cited work in the exact niche, not the general area.

Each of these is something you can check against your own draft today, which is the point: a Biotechnology Advances reject is usually a reframing problem you can diagnose before you choose the next journal.

A review-journal rejection is different from a research-paper rejection, and the difference matters here. With a research paper, a reject often means new experiments. With a review, a Biotechnology Advances reject usually means the synthesis needs reframing, not that you need new data.

Don't just resubmit the same manuscript down the ladder. If the editor rejected for weak critical synthesis or redundancy, the next serious review journal will see the same problem. The same reviewers sometimes see it again, because the pool of specialists for a given biotechnology niche is small. Before you move, decide honestly whether the manuscript takes a defensible position or merely describes the field. If it describes, reframe it around one load-bearing claim before sending it anywhere.

There is one case where moving fast is right: a clean scope mismatch. If Biotechnology Advances rejected because the work is primary data, not a review, do not try to rewrite it into a review. Send it to Metabolic Engineering or Bioresource Technology as the research paper it already is.